Skip to content

Emotional Eating, Sleep Quality, Mental State and Metabolic Syndrome

The Mediating Role of Emotional Eating and Sleep Quality in the Relationship Between Mental State and Metabolic Syndrome in Individuals With Schizophrenia and Bipolar Disorder

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07411222
Enrollment
78
Registered
2026-02-13
Start date
2026-05-30
Completion date
2026-12-01
Last updated
2026-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bipolar Disorder, Emotional Eating, Mediating, Metabolic Syndrome, Psychiatric Issue, Schizophrenia, Sleep

Keywords

Schizophrenia, Bipolar Disorder, Metabolic Syndrome, Emotional Eating, Sleep

Brief summary

In predominantly medication-naïve schizophrenic patients, those exhibiting partial metabolic disorders have significantly worse sleep quality and sleep onset time; poor sleep predicted metabolic dysregulation even after controlling for confounding factors. Mental health, sleep, and eating behavior interact in ways that strongly influence the risk of obesity and MetS. Emotional eating (eating in response to emotions rather than hunger) is central to this network and appears to be closely associated with psychiatric illnesses, particularly depression, anxiety, and sleep disorders. There is a continuing need to elucidate the frequency, level, and relationship of emotional eating with other factors in individuals with SMI. Therefore, this study aims to elucidate this complex relationship, thereby shedding light on new ways to reduce metabolic risks in psychiatric patients.

Detailed description

Research Questions * Is there a relationship between mental status and MetS in individuals with SMI? * How does diagnosis (schizophrenia or bipolar disorder) and the group of medications used affect MetS in individuals with SMI? * What is the level of emotional eating in individuals with SMI? * Do emotional eating and sleep quality affect MetS in relation to mental status in individuals with SMI? Hypotheses H1 The group of psychotropic medications routinely used significantly affects MetS levels. H2 Individuals with SMI have high levels of emotional eating. H3 As mental status deteriorates, the level of emotional eating increases. H4 Emotional eating mediates the relationship between mental status and MetS. H5 Sleep quality mediates the relationship between mental status and MetS. H6 Emotional eating and sleep quality mediate the relationship between mental status and MetS (multiple mediation model). H7 As sleep quality decreases, emotional eating increases. H8 As the level of emotional eating increases, sleep quality deteriorates, which increases the risk of metabolic syndrome.

Interventions

None listed

Sponsors

Abant Izzet Baysal University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Being registered with the Bolu İzzet Baysal Mental Health and Diseases Hospital Community Mental Health Center, * Having a severe chronic psychiatric illness (Schizophrenia Spectrum and Other Psychotic Disorders and Bipolar Disorder) followed by the Bolu İzzet Baysal Mental Health and Diseases Hospital Community Mental Health Center for at least 6 months, * Being in remission (Complete Remission (Pre-Remission): Symptoms remaining below threshold values for at least 2 months (8 weeks). A state of improvement lasting more than 2 months is generally referred to as "remission"), * Schizophrenia remission definition: 8 diagnostically significant symptoms were selected from the Positive and Negative Syndrome Scale. * Bipolar disorder remission definition: Complete remission is defined as the absence of acute attacks and the presence of minimal/very mild symptoms. * Being between 18-65 years of age, * Being able to understand what is read and give written consent.

Exclusion criteria

* Having a diagnosis of mental retardation, * Having other neurocognitive disorders, primarily dementia, according to DSM-V (as it can affect the ability to make decisions and give correct answers), * Not being able to speak or understand Turkish.

Design outcomes

Primary

MeasureTime frameDescription
Metabolic Syndrome RiskBaselineParticipants' current metabolic syndrome risk scores will be measured using the Metabolic Syndrome Risk Index. The total score ranges from 0 to 100. A higher score indicates a higher risk of metabolic syndrome risk.

Secondary

MeasureTime frameDescription
Emotional eating levelBaselineParticipants' current emotional eating level scores will be measured using the Salzburg Emotional Eating Scale.
Sleep qualityBaselineParticipants' current sleep quality scores will be measured using the Cumhuriyet Subjective Sleep Quality Scale.
Positive and negative symptomBaselineParticipants' current positive and negative symptom severity. This will be measured using Positive and Negative Syndrome Scale (PANSS). It measures the prevalence of positive and negative syndromes in schizophrenia. Scores range from 7-49 for the Positive and Negative Scales, and from 16-112 for the General Psychopathology Scale. The PANSS total score is a minimum of 30 and a maximum of 210. A higher score indicates higher symptom severity.
Manic symptomBaselineParticipants' current manic symptom severity. This will be measured using Young Mania Rating Scale. It measures the prevalence of manic symptom in bipolar disorders. The total score can range from 0 to 60; higher scores indicate more severe manic symptoms.
Depressive symptomsBaselineParticipants' current depressive symptoms severity. This will be measured using Hamilton Depression Rating Scale. It measures the prevalence of depressive symptom. In general, the higher the total score, the more severe the depression. HAM-D depression score levels: 10-13 mild; 14-17 mild to moderate; \>17 moderate to severe; \>23 very severe. Total score ranges from 0 to 68.

Countries

Turkey (Türkiye)

Contacts

CONTACTMelisa Bulut, PhD
melisa.bulut@ibu.edu.tr+905348855882
CONTACTNur Özgedik Turhan, Psychiatrist
drnurozgedik@gmail.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 28, 2026